Plan B Delay Draws Criticism From Congress, Academia, FDA Official

Related Articles: 15

Elsevier Business Intelligence Publications

• Click an article headline for more information.
• Plan C? The Plan B Decision and Calls for a Third Class of Drugs
  The RPM Report December 2011
• Galson Backed Initial Plan B Denial In Fear His Job Was In Jeopardy – Jenkins
  “The Pink Sheet” Sep. 4, 2006
• FDA Morale Improvement Will Be A Priority, Von Eschenbach Testifies
  “The Pink Sheet” Aug. 7, 2006
• FDA Depositions Reveal Crawford’s Prominent Role In Plan B Switch Review
  “The Pink Sheet” May 29, 2006
• Von Eschenbach’s FDA Will Be A “Facilitating Agency,” Nominee Says
  “The Pink Sheet” Mar. 20, 2006
• Xenical OTC Switch Could Require More Actual Use Study, Committees Say
  “The Pink Sheet” Jan. 30, 2006
• Safety And FDA’s Centennial: As The Agency Turns 100, “Adulterated Drugs” Is Taking On A Whole New Meaning
  “The Pink Sheet” Jan. 16, 2006
• Xenical Long-Term Switch Odds Carry More Weight, Experts Say
  “The Pink Sheet” Jan. 2, 2006
• Office of Women’s Health director named
  “The Pink Sheet” Nov. 28, 2005
• Plan B, FDA Acting Commissioner Used To Spotlight Conflict-Of-Interest Bill
  “The Pink Sheet” Oct. 17, 2005
• FDA Works To Stay Focused As Heads Spin; Deputy Commissioners In Spotlight
  “The Pink Sheet” Oct. 3, 2005
• Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA
  “The Pink Sheet” Sep. 26, 2005
• Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance
  “The Pink Sheet” Sep. 19, 2005
• Crawford’s First Business After Confirmation: Brief Senators On Mifeprex
  “The Pink Sheet” Jul. 25, 2005
• Plan B “Not Approvable” Decision Puts FDA, CDER Director In Hot Seat
  “The Pink Sheet” May 10, 2004

Topics Covered in this Article

• Click a keyword for related articles.